Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts – the CONFIDENCE study protocol

Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts – the CONFIDENCE study protocol

Abstract Background Multiple sclerosis (MS) is a chronic disease that requires lifelong treatment. A highly effective drug not only for relapsing but also for progressive forms of MS with a favorable safety profile is needed to further improve overall patient outcomes. Ocrelizumab, a recombinant hum...

Full description

Bibliographic Details
Main Authors: Petra Dirks, Vera Zingler, Jost Leemhuis, Heike Berthold, Stefanie Hieke-Schulz, David Wormser, Tjalf Ziemssen
Format: Article
Language:English
Published: BMC 2020-03-01
Series:BMC Neurology
Subjects:
Ocrelizumab
Relapsing multiple sclerosis
Primary progressive multiple sclerosis
Real world data
Non-interventional study
Long-term safety and effectiveness
Online Access:http://link.springer.com/article/10.1186/s12883-020-01667-7

Internet

http://link.springer.com/article/10.1186/s12883-020-01667-7

Similar Items